OpGen Provides Preliminary Unaudited Revenue for FY 2022 and Business Update
18 janv. 2023 07h30 HE
|
OpGen, Inc.
Preliminary full year revenue for 2022 of approximately $ 2.7 million is within most recent guidance rangeCash position as of December 31, 2022 was approximately $7.4 millionBalance sheet strengthened...
OpGen Subsidiary Curetis Meets Several Key Milestones in FIND Collaboration Project
17 janv. 2023 07h30 HE
|
OpGen, Inc.
ROCKVILLE, Md., Jan. 17, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics...
OpGen Announces Closing of $7.5 Million Public Offering
11 janv. 2023 16h30 HE
|
OpGen, Inc.
ROCKVILLE, Md., Jan. 11, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics...
OpGen Announces Pricing of $7.5 Million Public Offering
06 janv. 2023 20h00 HE
|
OpGen, Inc.
ROCKVILLE, Md., Jan. 06, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics...
OpGen Announced 1-for-20 Reverse Stock Split
04 janv. 2023 16h30 HE
|
OpGen, Inc.
ROCKVILLE, Md., Jan. 04, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics...
OpGen Announces Positive Top Line Data from Clinical Trial for Unyvero Urinary Tract Infection Panel
13 déc. 2022 07h30 HE
|
OpGen, Inc.
Study has enrolled over 1,800 patient samples at 4 U.S. clinical trial sitesPrimary endpoint for Unyvero UTI for urinary tract infection shows overall weighted average sensitivity of 96.4% and overall...
OpGen Reports Third Quarter 2022 Financial Results and Provides Business Update
10 nov. 2022 16h10 HE
|
OpGen, Inc.
Completes first two commercial customer installations for Acuitas AMR Gene PanelOpGen subsidiary, Curetis, signed collaboration agreement with BioVersys AG and R&D collaboration agreement with...
OpGen Announces Preliminary Unaudited Revenue and Cash Position for Third Quarter 2022 and Provides Business Update
27 oct. 2022 07h30 HE
|
OpGen, Inc.
Preliminary Total Revenue for Q3 2022 was approximately $0.4 millionCash as of September 30, 2022 was approximately $10.3 million and as of October 3, 2022 was approximately $13.3 millionAdditional...
OpGen to Provide Business Update and Financial Results for the Third Quarter 2022 on November 10th at 4:30 p.m. Eastern Standard Time
27 oct. 2022 07h30 HE
|
OpGen, Inc.
ROCKVILLE, Md., Oct. 27, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its third quarter...
OpGen Subsidiary Curetis and BioVersys Sign Collaboration Agreement for Clinical Trial Support
25 oct. 2022 07h30 HE
|
OpGen, Inc.
Unyvero platform for rapid diagnostics to be used in Phase II clinical trial of BV100Focus on the detection of pneumonia patients infected with Acinetobacter baumannii ROCKVILLE, Md. and BASEL,...